中国乙肝药物治疗市场究竟多大？
The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of 18%.
Decision Resources puts the current count of people in China with chronic hepatitis B at 80 million, though other reports estimate the total is 50% higher – 120 million. That constitutes almost 10% of the population. Part of the reason behind the high dollar value of drugs for this population is that the nucleoside/nucleotide analogue class of drugs often used to treat the disease must be given long term, often for the rest of a patient’s life. In most cases, these drugs are effective, suppressing the viral count, but the disease reappears as soon as treatment is discontinued.
For China’s patients, the choice is often between a more-expensive Western drug and a domestic treatment that is perceived to be less effective. According to Dr. Victor Li, an analyst at Decision Resources, the increasing use of Western remedies is one of the factors driving the market higher. "The shift to use more expensive Western branded drugs, particularly newer agents such as Bristol-Myers Squibb's (BMY) Baraclude, Roche's (RHHBY.PK) Pegasys and Schering-Plough's (SGP) Pegintron, will contribute significantly to the expansion of the hepatitis B market in China," he said.
Among domestically produced drugs, Tianjin Institute of Pharmaceutical Research's Dai Ding (adefovir) has achieved the highest market share, topping even Hepsera from GlaxoSmithKline (GSK).
阿德福韦国产多了，这帮医生就开恩提卡韦，长效干扰素，够狠啊（依据也充分，毕竟是一线用药嘛）！销售额能不长吗
The market for hepatitis B drugs in China is expected to grow 135% by 2012, according to a new report from Decision Resources. From $340 million in 2007, sales of hepatitis B treatments will increase to $800 million over the five years, a CAGR of 18%.
Decision Resources puts the current count of people in China with chronic hepatitis B at 80 million, though other reports estimate the total is 50% higher – 120 million. That constitutes almost 10% of the population. Part of the reason behind the high dollar value of drugs for this population is that the nucleoside/nucleotide analogue class of drugs often used to treat the disease must be given long term, often for the rest of a patient’s life. In most cases, these drugs are effective, suppressing the viral count, but the disease reappears as soon as treatment is discontinued.
For China’s patients, the choice is often between a more-expensive Western drug and a domestic treatment that is perceived to be less effective. According to Dr. Victor Li, an analyst at Decision Resources, the increasing use of Western remedies is one of the factors driving the market higher. "The shift to use more expensive Western branded drugs, particularly newer agents such as Bristol-Myers Squibb's (BMY) Baraclude, Roche's (RHHBY.PK) Pegasys and Schering-Plough's (SGP) Pegintron, will contribute significantly to the expansion of the hepatitis B market in China," he said.
Among domestically produced drugs, Tianjin Institute of Pharmaceutical Research's Dai Ding (adefovir) has achieved the highest market share, topping even Hepsera from GlaxoSmithKline (GSK).
阿德福韦国产多了，这帮医生就开恩提卡韦，长效干扰素，够狠啊（依据也充分，毕竟是一线用药嘛）！销售额能不长吗